Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q4 2023 ▲▼ | Q1 2024 ▲▼ | Change ▲▼ | Q4 2023 ▲▼ | Q1 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Newamsterdam Pharma Company ORDINARY SHARES | 11,831,461 | 11,831,461 | 0 | $132.16M | $279.81M | 39.56% | +$147.66M |
| Dyne Therapeutics, Inc.(DYN) | 6,131,079 | 7,845,364 | +1,714,285 | $81.54M | $222.73M | 31.49% | +$141.19M |
| Engene Holdings Inc COM | 8,677,951 | 8,677,951 | 0 | $80.10M | $147.09M | 20.79% | +$66.99M |
| Replimune Group, Inc.(REPL) | 4,866,499 | 4,866,449 | -50 | $41.02M | $39.76M | 5.62% | -$1.27M |
| Engene Holdings IncW EXP 10 31 2028 *W EXP 10/31/202 | 3,878,148 | 2,878,148 | -1,000,000 | $2.45M | $14.97M | 2.12% | +$12.52M |
| Achilles Therapeutics PlcADS | 2,390,050 | 2,390,050 | 0 | $2.13M | $2.99M | 0.42% | +$860.4K |